Advertisement

Endocrine Pathology

, Volume 25, Issue 1, pp 65–79 | Cite as

Neuroendocrine Tumors of the Pancreas: Current Concepts and Controversies

  • Michelle D. Reid
  • Serdar Balci
  • Burcu Saka
  • N. Volkan AdsayEmail author
Article

Abstract

In the past decade, the clinico-pathologic characteristics of neuroendocrine tumors (NETs) in the pancreas have been further elucidated. Previously termed “islet cell tumors/carcinomas” or “endocrine neoplasms”, they are now called pancreatic NETs (PanNETs). They occur in relatively younger patients and may arise anywhere in the pancreas. Some are associated with von Hippel–Lindau, MEN1, and other syndromes. It is now widely recognized that, with the exception of tumorlets (minute incipient neoplasms) that occur in some syndromes like MEN1, all PanNETs are malignant, albeit low-grade, and although they have a protracted clinical course and overall 10-year survival of 60–70 %, even low-stage and low-grade examples may recur and/or metastasize on long-term follow-up. Per recent consensus guidelines adopted by both European and North American NET Societies (ENETS and NANETs) and WHO-2010, PanNETs are now graded and staged separately, unlike previous classification schemes that used a combination of grade, stage, and adjunct prognosticators in an attempt to define “benign behavior” or “malignant” categories. For staging, the ENETs proposal may be more applicable than CAP/AJCC, which is based on the staging of exocrine tumors. Current grading of PanNETs is based on mitotic activity and ki-67 index. Other promising prognosticators such as necrosis, CK19, c-kit, and others are still under investigation. It has also been recognized that PanNETs have a rather wide morphologic repertoire including oncocytic, pleomorphic, ductulo-insular, sclerosing, and lipid-rich variants. Most PanNETs are diagnosed by fine needle aspiration biopsy, in which single, monotonous plasmacytoid cells with fair amounts of cytoplasm and distinctive neuroendocrine chromatin are diagnostic. Molecular alterations of PanNETs are also very different than that of ductal or acinar tumors. Loss of expression of DAXX and ATRX proteins has been recently identified in 45 %. Along with these improvements, several controversies remain, including grading, value of current cutoff ranges, and the best methods for counting ki-67 index (manual count by computer-captured image may be the most practical for the time being). More important is the controversial use of the term “carcinoma”, which was previously employed in WHO-2004 only for invasive and metastatic cases but has now been made synonymous with grade 3 group of tumors. It is becoming clear that grade 3 group comprises two distinct categories: (1) differentiated but proliferatively more active tumors which typically have ki-67 indices in the 20–50 % range and (2) true poorly differentiated NE carcinomas as defined in the lung, with ki-67 typically >50 %. Further studies are needed to address these controversial aspects of PanNETs.

Keywords

Pancreas Neuroendocrine tumor WDNET PDNEC 

References

  1. 1.
    Klimstra D, Arnold R, Capella C, Hruban R, Kloppel G, Komminoth P, Solcia E, Rindi G (2010) Neuroendocrine neoplasms of the pancreas. In: Bosman F, Carneiro F, Hruban R, Theise N (eds) WHO classification of tumours of the digestive system, 3rd edn. IARC, Lyon, pp 322-326Google Scholar
  2. 2.
    Vagefi PA, Razo O, Deshpande V, McGrath DJ, Lauwers GY, Thayer SP, Warshaw AL, Fernandez-Del Castillo C (2007) Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. Arch Surg 142 (4):347-354. doi: 10.1001/archsurg.142.4.347 PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Anlauf M, Schlenger R, Perren A, Bauersfeld J, Koch CA, Dralle H, Raffel A, Knoefel WT, Weihe E, Ruszniewski P, Couvelard A, Komminoth P, Heitz PU, Kloppel G (2006) Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol 30 (5):560-574. doi: 10.1097/01.pas.0000194044.01104.25 PubMedCrossRefGoogle Scholar
  4. 4.
    Lubensky IA, Pack S, Ault D, Vortmeyer AO, Libutti SK, Choyke PL, Walther MM, Linehan WM, Zhuang Z (1998) Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol 153 (1):223-231. doi: 10.1016/S0002-9440(10)65563-0 PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Hoang MP, Hruban RH, Albores-Saavedra J (2001) Clear cell endocrine pancreatic tumor mimicking renal cell carcinoma: a distinctive neoplasm of von Hippel–Lindau disease. Am J Surg Pathol 25 (5):602-609PubMedCrossRefGoogle Scholar
  6. 6.
    Fryer E, Serra S, Chetty R (2012) Lipid-rich (“clear cell”) neuroendocrine tumors of the pancreas in MEN I patients. Endocr Pathol 23 (4):243-246. doi: 10.1007/s12022-012-9221-z PubMedCrossRefGoogle Scholar
  7. 7.
    Whipple AO, Frantz VK (1935) Adenoma of islet cells with hyperinsulinism: a review. Ann Surg 101 (6):1299-1335PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Shi C, Siegelman SS, Kawamoto S, Wolfgang CL, Schulick RD, Maitra A, Hruban RH (2010) Pancreatic duct stenosis secondary to small endocrine neoplasms: a manifestation of serotonin production? Radiology 257 (1):107-114. doi: 10.1148/radiol.10100046 PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Kenney B, Singh G, Salem RR, Paterno F, Robert ME, Jain D (2011) Pseudointraductal papillary mucinous neoplasia caused by microscopic periductal endocrine tumors of the pancreas: a report of 3 cases. Hum Pathol 42 (7):1034-1041. doi: 10.1016/j.humpath.2010.09.018 PubMedCrossRefGoogle Scholar
  10. 10.
    Basturk O, Yang Z, Tang LH, Hruban R, McCall C, Adsay V, Krasinskas A, Jang KT, Bellizzi A, Shi C, Klimstra DS (2013) Increased (> 20 %) Ki67 proliferation index in morphologically well differentiated pancreatic neuroendocrine tumors (PanNETs) correlates with decreased overall survival (abstract). Modern Pathology 26:423A-423AGoogle Scholar
  11. 11.
    Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U (2013) Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 24 (1):152-160. doi: 10.1093/annonc/mds276 CrossRefGoogle Scholar
  12. 12.
    Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF, Klimstra DS (2002) Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 20 (11):2633-2642PubMedCrossRefGoogle Scholar
  13. 13.
    Deshpande V, Fernandez-del Castillo C, Muzikansky A, Deshpande A, Zukerberg L, Warshaw AL, Lauwers GY (2004) Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors. Am J Surg Pathol 28 (9):1145-1153PubMedCrossRefGoogle Scholar
  14. 14.
    Jain R, Fischer S, Serra S, Chetty R (2010) The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver. Appl Immunohistochem Mol Morphol 18 (1):9-15. doi: 10.1097/PAI.0b013e3181ad36ea PubMedCrossRefGoogle Scholar
  15. 15.
    Schmitt AM, Anlauf M, Rousson V, Schmid S, Kofler A, Riniker F, Bauersfeld J, Barghorn A, Probst-Hensch NM, Moch H, Heitz PU, Kloeppel G, Komminoth P, Perren A (2007) WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol 31 (11):1677-1682. doi: 10.1097/PAS.0b013e31805f675d PubMedCrossRefGoogle Scholar
  16. 16.
    Zhang L, Smyrk TC, Oliveira AM, Lohse CM, Zhang S, Johnson MR, Lloyd RV (2009) KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers. Am J Surg Pathol 33 (10):1562-1569. doi: 10.1097/PAS.0b013e3181ac675b PubMedCrossRefGoogle Scholar
  17. 17.
    Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS (2012) Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol 36 (12):1761-1770. doi: 10.1097/PAS.0b013e318263207c PubMedCrossRefGoogle Scholar
  18. 18.
    Bagci P, Ohike N, Dursun N, Jang K, Tajin T, Basturk O, Konh SY, Ducato L, Reid M, Adsay V (2012) Comparative analysis of different methodologies for ki67 in pancreatic neuroendocrine tumors (abstract). Modern Pathol 25;441A-441AGoogle Scholar
  19. 19.
    AJCC (2010) Cancer staging manual, 7th edn edn. Springer, New YorkGoogle Scholar
  20. 20.
    Sobin L, Gospodarowicz M, Wittekind C (2009) UICC: TNM classification of malignant tumors, 7th edn. Wiley-Blackwell, OxfordGoogle Scholar
  21. 21.
    CAP (2013) College of american pathologists cancer protocols and checklists. College of American Pathologists. http://www.cap.org/. Accessed 04/10/2013
  22. 22.
    Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449 (4):395-401. doi: 10.1007/s00428-006-0250-1 PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Adsay NV, Bagci P, Tajiri T, Oliva I, Ohike N, Balci S, Gonzalez RS, Basturk O, Jang KT, Roa JC (2012) Pathologic staging of pancreatic, ampullary, biliary, and gallbladder cancers: pitfalls and practical limitations of the current AJCC/UICC TNM staging system and opportunities for improvement. Seminars in Diagnostic Pathology 29 (3):127-141. doi: 10.1053/j.semdp.2012.08.010 PubMedCrossRefGoogle Scholar
  24. 24.
    Saka B, Oliva I, Bandyopadhyay S, Basturk O, Balci S, Maithel S, Kooby D, Sarmiento J, Staley C, El-Rayes B, Choi H, Knight J, Krasinskas A, Adsay V (2014) Will the pT1 and pT2 pancreas cancer please stand up? “Peripancreatic soft tissue” is involved in most pancreatic ductal adenocarcinomas (PDAC), negating its value as a staging parameter and necessitating a new staging scheme (abstract). Modern Pathology 27(Supplement), in pressGoogle Scholar
  25. 25.
    Saka B, Balci S, Bagci P, Maithel S, Kooby D, Sarmiento J, Staley C, El-Rayes B, Choi H, Knight J, Goodman M, Krasinskas A, Adsay V (2014) Proposal for a new and prognostically valuable tumor size based T-stage for pancreatic adenocarcinoma (abstract). Modern Pathology 27(Supplement), in pressGoogle Scholar
  26. 26.
    Rindi G, Falconi M, Klersy C, Albarello L, Boninsegna L, Buchler MW, Capella C, Caplin M, Couvelard A, Doglioni C, Delle Fave G, Fischer L, Fusai G, de Herder WW, Jann H, Komminoth P, de Krijger RR, La Rosa S, Luong TV, Pape U, Perren A, Ruszniewski P, Scarpa A, Schmitt A, Solcia E, Wiedenmann B (2012) TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 104 (10):764-777. doi: 10.1093/jnci/djs208 PubMedCrossRefGoogle Scholar
  27. 27.
    Rindi G, de Herder WW, O'Toole D, Wiedenmann B (2006) Consensus guidelines for the management of patients with digestive neuroendocrine tumors: why such guidelines and how we went about it. Neuroendocrinology 84 (3):155-157. doi: 10.1159/000098006 PubMedCrossRefGoogle Scholar
  28. 28.
    Liszka L, Pajak J, Mrowiec S, Zielinska-Pajak E, Golka D, Lampe P (2011) Discrepancies between two alternative staging systems (European Neuroendocrine Tumor Society 2006 and American Joint Committee on Cancer/Union for International Cancer Control 2010) of neuroendocrine neoplasms of the pancreas. A study of 50 cases. Pathol Res Pract 207 (4):220-224. doi: 10.1016/j.prp.2011.01.008 PubMedCrossRefGoogle Scholar
  29. 29.
    Anlauf M, Perren A, Kloppel G (2007) Endocrine precursor lesions and microadenomas of the duodenum and pancreas with and without MEN1: criteria, molecular concepts and clinical significance. Pathobiology 74 (5):279-284. doi: 10.1159/000105810 PubMedCrossRefGoogle Scholar
  30. 30.
    Laidlaw GF (1938) Nesidioblastoma, the islet tumor of the pancreas. Am J Pathol 14 (2):125-134 125Google Scholar
  31. 31.
    Vance JE, Stoll RW, Kitabchi AE, Williams RH, Wood FC, Jr. (1969) Nesidioblastosis in familial endocrine adenomatosis. JAMA 207 (9):1679-1682PubMedCrossRefGoogle Scholar
  32. 32.
    Heitz PU, Kasper M, Polak JM, Kloppel G (1979) Pathology of the endocrine pancreas. J Histochem Cytochem 27 (10):1401-1402PubMedCrossRefGoogle Scholar
  33. 33.
    Kloppel G, Anlauf M, Raffel A, Perren A, Knoefel WT (2008) Adult diffuse nesidioblastosis: genetically or environmentally induced? Hum Pathol 39 (1):3-8. doi: 10.1016/j.humpath.2007.09.010 PubMedCrossRefGoogle Scholar
  34. 34.
    Perez-Montiel MD, Frankel WL, Suster S (2003) Neuroendocrine carcinomas of the pancreas with 'Rhabdoid' features. Am J Surg Pathol 27 (5):642-649PubMedCrossRefGoogle Scholar
  35. 35.
    Zee SY, Hochwald SN, Conlon KC, Brennan MF, Klimstra DS (2005) Pleomorphic pancreatic endocrine neoplasms: a variant commonly confused with adenocarcinoma. Am J Surg Pathol 29 (9):1194-1200PubMedCrossRefGoogle Scholar
  36. 36.
    Garbrecht N, Anlauf M, Schmitt A, Henopp T, Sipos B, Raffel A, Eisenberger CF, Knoefel WT, Pavel M, Fottner C, Musholt TJ, Rinke A, Arnold R, Berndt U, Plockinger U, Wiedenmann B, Moch H, Heitz PU, Komminoth P, Perren A, Kloppel G (2008) Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer 15 (1):229-241. doi: 10.1677/ERC-07-0157 PubMedCrossRefGoogle Scholar
  37. 37.
    McCall CM, Shi C, Klein AP, Konukiewitz B, Edil BH, Ellison TA, Wolfgang CL, Schulick RD, Kloppel G, Hruban RH (2012) Serotonin expression in pancreatic neuroendocrine tumors correlates with a trabecular histologic pattern and large duct involvement. Hum Pathol 43 (8):1169-1176. doi: 10.1016/j.humpath.2011.09.014 PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Basturk O, Hruban R, Adsay V, Krasinskas A, Jang KT, Liu X, Vakiani E, Zhang L, Frankel W, Giordano T, Bellizzi A, Chen JH, Deshpande V, Yang Z, Klimstra DS (2013) High-grade neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 60 cases (abstract). Modern Pathology 26:422A-423ACrossRefGoogle Scholar
  39. 39.
    Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA, Jr., Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N (2011) DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331 (6021):1199-1203. doi: 10.1126/science.1200609 PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Agaimy A, Erlenbach-Wunsch K, Konukiewitz B, Schmitt AM, Rieker RJ, Vieth M, Kiesewetter F, Hartmann A, Zamboni G, Perren A, Kloppel G (2013) ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin. Mod Pathol 26 (7):995-1003. doi: 10.1038/modpathol.2013.40 PubMedCrossRefGoogle Scholar
  41. 41.
    Graham RP, Shrestha B, Caron BL, Smyrk TC, Grogg KL, Lloyd RV, Zhang L (2013) Islet-1 is a sensitive but not entirely specific marker for pancreatic neuroendocrine neoplasms and their metastases. Am J Surg Pathol 37 (3):399-405. doi: 10.1097/PAS.0b013e31826f042c PubMedCrossRefGoogle Scholar
  42. 42.
    Chan ES, Alexander J, Swanson PE, Jain D, Yeh MM (2012) PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms. Am J Surg Pathol 36 (5):737-743. doi: 10.1097/PAS.0b013e31824aba59 PubMedCrossRefGoogle Scholar
  43. 43.
    Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, de Wilde RF, Maitra A, Hicks J, Demarzo AM, Shi C, Sharma R, Laheru D, Edil BH, Wolfgang CL, Schulick RD, Hruban RH, Tang LH, Klimstra DS, Iacobuzio-Donahue CA (2012) Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 36 (2):173-184. doi: 10.1097/PAS.0b013e3182417d36 PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Gortz B, Roth J, Krahenmann A, de Krijger RR, Muletta-Feurer S, Rutimann K, Saremaslani P, Speel EJ, Heitz PU, Komminoth P (1999) Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms. Am J Pathol 154 (2):429-436. doi: 10.1016/S0002-9440(10)65289-3 PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Hessman O, Lindberg D, Skogseid B, Carling T, Hellman P, Rastad J, Akerstrom G, Westin G (1998) Mutation of the multiple endocrine neoplasia type 1 gene in nonfamilial, malignant tumors of the endocrine pancreas. Cancer Res 58 (3):377-379PubMedGoogle Scholar
  46. 46.
    Toliat MR, Berger W, Ropers HH, Neuhaus P, Wiedenmann B (1997) Mutations in the MEN I gene in sporadic neuroendocrine tumours of gastroenteropancreatic system. Lancet 350 (9086):1223. doi: 10.1016/S0140-6736(05)63453-8 PubMedGoogle Scholar
  47. 47.
    Wang EH, Ebrahimi SA, Wu AY, Kashefi C, Passaro E, Jr., Sawicki MP (1998) Mutation of the MENIN gene in sporadic pancreatic endocrine tumors. Cancer Res 58 (19):4417-4420PubMedGoogle Scholar
  48. 48.
    Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He Y, Yan H, Bigner DD, Oba-Shinjo SM, Marie SK, Riggins GJ, Kinzler KW, Vogelstein B, Hruban RH, Maitra A, Papadopoulos N, Meeker AK (2011) Altered telomeres in tumors with ATRX and DAXX mutations. Science 333 (6041):425. doi: 10.1126/science.1207313 PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364 (6):514-523. doi: 10.1056/NEJMoa1009290 PubMedCrossRefGoogle Scholar
  50. 50.
    Wood L, Adsay N, Hruban R (2013) Molecular pathology of pancreatic cancer. In: Cheng L, Eble J (eds) Molecular surgical pathology. Springer, New York, pp 17-42CrossRefGoogle Scholar
  51. 51.
    Meriden Z, Shi C, Edil BH, Ellison T, Wolfgang CL, Cornish TC, Schulick RD, Hruban RH (2011) Hyaline globules in neuroendocrine and solid-pseudopapillary neoplasms of the pancreas: a clue to the diagnosis. Am J Surg Pathol 35 (7):981-988. doi: 10.1097/PAS.0b013e31821a9a14 PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Adsay NV, Andea A, Basturk O, Kilinc N, Nassat H, Cheng JD (2004) Secondary tumors of the pancreas: ana analysis of a surgical and autopsy database and review of the literature. Virchows Archiv 444(6):527-535Google Scholar
  53. 53.
    Bismar TA, Basturk O, Gerald WL, Schwarz K, Adsay NV (2004) Desmoplastic small cell tumor in the pancreas. Am J Surg Pathol 28 (6):808-812PubMedCrossRefGoogle Scholar
  54. 54.
    Movahedi-Lankarani S, Hruban RH, Westra WH, Klimstra DS (2002) Primitive neuroectodermal tumors of the pancreas: a report of seven cases of a rare neoplasm. Am J Surg Pathol 26 (8):1040-1047PubMedCrossRefGoogle Scholar
  55. 55.
    Bachmann J, Kleeff J, Bergmann F, Shrikhande SV, Hartschuh W, Buchler MW, Friess H (2005) Pancreatic metastasis of Merkel cell carcinoma and concomitant insulinoma: case report and literature review. World J Surg Oncol 3:58. doi: 10.1186/1477-7819-3-58 PubMedCentralPubMedCrossRefGoogle Scholar
  56. 56.
    Fung AD, Cohen C, Kavuri S, Lawson D, Gao X, Reid MD (2013) Phosphohistone h3 and ki-67 labeling indices in cytologic specimens from well-differentiated neuroendocrine tumors of the gastrointestinal tract and pancreas: a comparative analysis using automated image cytometry. Acta Cytol 57 (5):501-508. doi: 10.1159/000351475 PubMedCrossRefGoogle Scholar
  57. 57.
    Larghi A, Capurso G, Carnuccio A, Ricci R, Alfieri S, Galasso D, Lugli F, Bianchi A, Panzuto F, De Marinis L, Falconi M, Delle Fave G, Doglietto GB, Costamagna G, Rindi G (2012) Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study. Gastrointest Endosc 76 (3):570-577. doi: 10.1016/j.gie.2012.04.477 PubMedCrossRefGoogle Scholar
  58. 58.
    Yang Z, Tang LH, Klimstra DS (2011) Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol 35 (6):853-860. doi: 10.1097/PAS.0b013e31821a0696 PubMedCrossRefGoogle Scholar
  59. 59.
    Velayoudom-Cephise FL, Duvillard P, Foucan L, Hadoux, J, Chougnet CN, Leboulleux, S, Malka D, Guigay J, Goere D, Debaere T, Caramella C, Schlumberger M, Planchard D, Elias D, Ducreux M, Scoazec JY, Baudin E (2013) Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer 20 (5):649-657. doi: 10.1530/ERC-13-0027
  60. 60.
    McCall CM, Shi C, Cornish TC, Klimstra DS, Tang LH, Basturk O, Mun LJ, Ellison TA, Wolfgang CL, Choti MA, Schulick RD, Edil BH, Hruban RH (2013) Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. Am J Surg Pathol 37 (11):1671-1677. doi: 10.1097/PAS.0000000000000089 PubMedCrossRefGoogle Scholar
  61. 61.
    Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC, Jensen RT (2010) NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 39 (6):735-752. doi: 10.1097/MPA.0b013e3181ebb168 PubMedCentralPubMedCrossRefGoogle Scholar
  62. 62.
    Metz DC, Jensen RT (2008) Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 135 (5):1469-1492. doi: 10.1053/j.gastro.2008.05.047 PubMedCentralPubMedCrossRefGoogle Scholar
  63. 63.
    Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F (2008) Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 26 (26):4311-4318. doi: 10.1200/JCO.2008.16.7858 PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Michelle D. Reid
    • 1
  • Serdar Balci
    • 1
  • Burcu Saka
    • 1
  • N. Volkan Adsay
    • 1
    • 2
    Email author
  1. 1.Department of PathologyEmory University School of MedicineAtlantaUSA
  2. 2.Department of PathologyEmory University HospitalAtlantaUSA

Personalised recommendations